BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/25/2025 4:18:19 PM | Browse: 5 | Download: 25
 |
Received |
|
2024-09-18 04:49 |
|
Peer-Review Started |
|
2024-09-18 04:49 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-12-18 11:02 |
|
Revised |
|
2024-12-31 22:43 |
|
Second Decision |
|
2025-01-08 02:37 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-01-08 07:13 |
|
Articles in Press |
|
2025-01-08 07:13 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2025-01-14 12:41 |
|
Typeset the Manuscript |
|
2025-01-17 12:02 |
|
Publish the Manuscript Online |
|
2025-03-25 16:18 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Hepatocellular carcinoma resistance to tyrosine kinase inhibitors: Current status and perspectives
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yu-Run Miao and Xiao-Jun Yang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| The National Health Commission's Key Laboratory of Gastrointestinal Tumor Diagnosis and Treatment for the Year 2022, National Health Commission's Master's and Doctoral/Postdoctoral Fund Project |
No. NHCDP2022001 |
| Gansu Provincial People's Hospital Doctoral Supervisor Training Project |
No. 22GSSYA-3 |
|
| Corresponding Author |
Xiao-Jun Yang, Associate Professor, Chief Physician, MD, Second Ward of General Surgery, Gansu Province People Hospital, No. 204 Donggang West Road, Chengguan District, Lanzhou 730000, Gansu Province, China. yangxjmd@aliyun.com |
| Key Words |
Tyrosine kinase inhibitor; Hepatocellular carcinoma; Resistance; Cancer therapy; Rho GTPase activating protein 12 |
| Core Tip |
This study reveals the potential clinical value of Rho GTPase activating protein 12 (ARHGAP12) and provided the target direction for clinical tyrosine kinase inhibitor resistance and highlights the potential role of ARHGAP12 in drug resistance by revealing its involvement in the focal adhesion pathway. Through gene enrichment and protein-protein interaction network analyses, it was found that ARHGAP12 might regulate integrin beta 1, impacting cell attachment, migration, and cytoskeleton interactions. |
| Publish Date |
2025-03-25 16:18 |
| Citation |
<p>Miao YR, Yang XJ. Hepatocellular carcinoma resistance to tyrosine kinase inhibitors: Current status and perspectives. <i>World J Gastrointest Oncol</i> 2025; 17(4): 101528</p> |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i4/101528.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i4.101528 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
